(Research Triangle Park, N.C.) Todd Blonshine, CEO of Mustard Tree Instruments® addressed an audience of over 75 members of the pharmaceutical, life sciences, and affiliated market sectors in the Research Triangle Park region as the featured speaker for November’s Innovation in RTP event. In his presentation, “Drug Shortages and Recalls: Redefining Quality Control in the Pharmaceutical Manufacturing Industry with A Purpose” Blonshine discussed the challenges of quality control issues with raw materials in the drug manufacturing process and how his company is helping to alleviate the strain on manufacturers through its innovations in analytical testing instrumentation. (more…)

(Research Triangle Park, N.C.) Quintiles announced today that it has sold its minority interest in Invida, an Asia Pacific commercial solutions joint venture, to the Italy-based Menarini Group, which is acquiring Invida in its entirety. Invida was formed in 2006 by Quintiles; The Zuellig Group; and TLS Beta Pte. Ltd., an Asia investment company. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that J. Donald deBethizy, Ph.D., President and Chief Executive Officer, is scheduled to present at the Lazard Capital Markets 8th Annual Healthcare Conference at The Pierre Hotel in New York City on Tuesday, November 15, 2011 at 1:30 p.m. Eastern Time. (more…)

(Research Triangle Park, N.C.) Quintiles’ ability to provide customers with actionable early-stage data to make better development decisions faster has taken a significant step forward with the closing of the previously announced agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today reported its financial results for the third quarter and nine months ended September 30, 2011. (more…)

(Research Triangle Park, N.C.) Quintiles is ranked 25th in the inaugural World’s Best Multinational Workplaces list from the Great Place to Work® Institute. The rankings were announced during a reception at the New York Stock Exchange, hosted by the Great Place to Work Institute. (more…)

(Research Triangle Park, N.C.) To provide a more comprehensive and efficient global solution for its laboratory customers, Quintiles today announced the signing of a definitive agreement to acquire Advion BioServices, a premier U.S.-based bioanalytical laboratory providing Good Laboratory Practice (GLP) pharmacokinetic/pharmacodynamic (PK/PD) testing and other services. Under the agreement, Quintiles will acquire Advion BioServices for an undisclosed amount of cash. Completion of the transaction, which is subject to usual and customary conditions, is expected this quarter. At that time it will join Quintiles as Advion Bioanalytical Labs, a Quintiles company. (more…)

(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Samuel P. Sears, Jr. has been appointed as an independent director of the Company effective October 21, 2011. (more…)

(Research Triangle Park, N.C.) With late phase (Phase IIIB and Phase IV) research becoming increasingly important to multiple healthcare stakeholders, Quintiles today announced it has acquired Outcome Sciences, Inc. (Outcome), a privately held outcomes research firm headquartered in Cambridge, Mass. The acquisition positions Quintiles as the industry powerhouse in late phase research, offering global reach, robust dedicated resources and specialization. (more…)

(Winston-Salem, N.C.) Targacept, Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics™, today announced the initiation of a potential registration study of AZD3480 in mild to moderate Alzheimer’s disease. The study is the subject of a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration. AZD3480 is licensed to AstraZeneca pursuant to a collaboration agreement focused in cognitive disorders. (more…)

(Research Triangle Park, N.C.) A perfect storm of stakeholder demands, unprecedented data access, new data channels and technologies is driving a dramatic shift in research methodologies among biopharmaceutical companies, according to a new report from Quintiles. The report, titled Methods Matter: Selecting the best real-world approach for evidence generation, states that biopharmaceutical firms are increasingly beginning with healthcare stakeholders’ needs when planning forward-looking, “real-world” research approaches. (more…)

(Research Triangle Park, N.C.) Quintiles was named 4th in the prestigious InformationWeek 500 technology innovators rankings for its Quintiles INFOSARIO™ platform in a gala awards ceremony at the St. Regis Monarch Beach Resort (California). The company was also recognized as the industry leader in the biotech and pharmaceutical category. (more…)